Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations

NeuroToxicology

Volumn 24, Issue 3, 2003, Pages 379-390

  Bowyer, John F ^a   Young, John F ^a   Slikker Jr , William ^a   Itzak, Yossef ^b   Mayorga, A J ^a   Newport, Glenn D ^a   Ali, Syed F ^a   Frederick, David L ^c   Paule, Merle G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Behavior and neurotoxicity; Ecstasy; Fenfluramine; Methylenedioxymethamphetamine; Pharmacokinetics; Primates

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DRUG METABOLITE; FENFLURAMINE; FLUOXETINE; NORFENFLURAMINE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; INSTRUMENTAL CONDITIONING; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; TEMPERATURE MEASUREMENT;

MACACA MULATTA; PRIMATES;

EID: 0038039180     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00030-5     Document Type: Article

References (59)

1. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR et al. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 1993;15:91-6.
2. Appel NM, Contrera JF, De Sousa EB. Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: evidence from immunocytochemical studies. J Pharmacol Exp Ther 1989;249:928-43.
3. Baumgarten G, Garattini S, Lorens S, Wurtman R. Dexfenfluramine and neurotoxicity. Lancet 1992;339:359.
4. Broening HW, Bowyer JF, Slikker Jr, W. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of MDMA-induced hyperthermia. J Pharmacol Exp Ther 1995;275:325-33.
5. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ("ecstasy"). JAMA 1987;258: 780-1.
6. Brown RM, Crane AM, Goldman PS. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey. Brain Res 1979;168:133-50.
7. Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative fatalities in South Australia - is "ecstasy" the culprit? Am J Forensic Med Pathol 1998;19:261-5.
8. Caccia S, Bergami A, Fracasso C, Garattini S, Campbell B. Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. Xenobiotica 1995;25:1143-50.
9. Cacoub P, Dorent R, Nataf P, Houppe JP, Piette JC, Godeau P et al. Pulmonary hypertension and dexfenfluramine. Eur J Clin Pharmacol 1995;48:81-3.
10. Campbell DB. The use of toxicokinetics for the safety assessment of drugs acting in the brain. Mol Neurobiol 1995;11:193-216.
11. Cheymol G, Weissenburger J, Poirer JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995;35:684-7.
12. Chu T, Kumagai Y, DiStefano EW, Cho AK. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 1996;51:789-96.
13. Cimbura G. 3,4-Methylenedioxyamphetamine (MDA): analytical and forensic aspects of fatal poisoning. J Forensic Sci 1972;17:329-33.
14. Clausing P, Rushing L, Newport GD, Bowyer JF. Determination of d-fenfluramine, d-norfenfluramine and fluoxetine in plasma, brain tissue and brain microdialysate using high-performance liquid chromatography after precolumn derivatization with dansyl-chloride. J Chrom B 1997;692:419-26.
15. Clausing P, Newport GD, Bowyer JF. d-Fenfluramine and norfenfluramine levels in brain microdialysate. J Pharmacol Exp Ther 1998;284:618-24.
16. Clineschmidt BV, Totaro JA, McGuffin JC, Pflueger AB. Fenfluramine: long-term reduction in brain serotonin (5-hydroxytryptamine). Eur J Pharmacol 1976;35:211-4.
17. Clineschmidt BV, Zacchei AG, Totaro JA, Pflueger AB, McGuffin JC, Wishousky TI. Fenfluramine and brain serotonin. Ann N Y Acad Sci 1978;305:222-41.
18. Doogan DP. Pulmonary hypertension and fenfluramine. Br Med J Clin Res Ed 1982;284:1403.
19. Elayan I, Gibb JW, Hanson GR, Foltz RL, Lim HK, Johnson M. Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4, 5-methylenedioxymethamphetamine or 2-hydroxy-4, 5-methylenedioxyamphetamine. Eur J Pharmacol 1992;221: 281-8.
20. Fallon JK, Kieman AT, Henry JA, Milligan PJ, Cowan DA, Hunt AJ. Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (ecstasy) in humans. Clin Chem 1999;45:1058-69.
21. Farfel GM, Seiden LS. Role of hyperthermia in the mechanisms of protection against serotonergic toxicity. 1. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther 1995;272:860-7.
22. Frith CH, Chang LW, Lattin DL, Walls RC, Hamm J, Doblin R. Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and rat. Fundam Appl Toxicol 1987;9:110-9.
23. Frederick DL, Ali SF, Gillam MP, Gossett J, Slikker Jr, W, Paule MG. Acute effects of dexfenfluramine (d-FEN) and methylenedioxyamphetamine (MDMA) before and after short-course, high-dose treatment. Proc NYAS 1998;844:183-90.
24. Gaylor DW, Slikker Jr, W. Risk assessment for neurotoxicants. NeuroToxicology 1990;11:211-8.
25. Gibb JW, Hanson GR, Johnson M. Effects of (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA] on brain dopamine. Neuroscience 1986;12:608.
26. Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 1998;30:371-9.
27. Harvey JA, McMaster SE. Fenfluramine: evidence for neurotoxic action on midbrain and long-term depletion of serotonin. Psychopharmacol Commun 1975;1:217-28.
28. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4- methylenedioxymethamphetamine ("ecstasy"). Lancet 1992; 340:384-7.
29. Insel TR, Battaglia G, Johannessen JN, Massa S, DeSouza EB. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989;249:713-20.
30. Kalia M. Reversible, short-lasting, and dose-dependent effect of (+)-fenfluramine on neocortical serotonergic axons. Brain Res 1990;548:111-25.
31. Kleven MS, Schuster CR, Seiden LS. Effect and depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J Pharmacol Exp Ther 1988;246:822-8.
32. Lane MA, Baer DJ, Rumpler WV, Weindruch R, Ingram DK, Tilmont EM et al. Calorie restriction lowers body temperature in rhesus monkeys, consistent with a postulated anti-aging mechanism in rodents. Proc Natl Acad Sci USA 1996;93: 4159-67.
33. Liester MB, Grob CS, Bravo GL, Walsh RN. Sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180:345-52.
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin reagent. J Biol Chem 1951;193: 265-75.
35. Malberg JE, Seiden LS. Administration of fenfluramine at different ambient temperatures produces different core temperature and 5-HT neurotoxicity profiles. Brain Res 1997;756: 101-7.
36. 3H]paroxetine binding in rat brain. J Neurochem 1988;50:1783-90.
37. Mas M, Farre M, de la Torre R, Roser PN, Ortuno J, Segura J et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999;290:136-45.
38. McCann UD, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J et al. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 1994;269:792-8.
39. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricuarte G. Positron emission tomography evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352:1433-7.
40. Miller DB, O'Callaghan JP. Environment-, drug- and stress- induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994;270:752-60.
41. Molliver DC, Molliver ME. Anatomic evidence for a neurotoxic effect of (+)-fenfluramine upon serotonergic projections in the rat. Brain Res 1990;511:165-8.
42. Moore KA, Mozayani A, Fierro MF, Poklis A. Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and methylene-dioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci Int 1996;83:111-9.
43. Paule MG. Use of the NCTR operant test battery in nonhuman primates. Neurotoxicol Teratol 1990;12:413-8.
44. Paule MG. Validation of a behavioral test battery for monkeys. In: Buccafusco JJ, editor. Methods of behavioral analysis in neuroscience. Boca Raton (FL): CRC Press; 2001. p. 281-94.
45. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4- methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988;1:273-7.
46. Ricaurte G, Bryan L, Strauss L, Seiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals: neurochemical and anatomical evidence. Science 1985;229:986-8.
47. Ricaurte GA, Molliver ME, Mertello MB, Katz JL, Wilson MA, Martello AL. Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet 1991;338:1487-8.
48. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 2002;297:2260-3.
49. Ritschel WA. AUC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis. Methods Find Exp Clin Pharmacol 1986;8:633-40.
50. Roche N, Labrune S, Braun JM, Huchon GJ. Pulmonary hypertension and dexfenfluramine. Lancet 1992;339:436-7.
51. Schmued L, Slikker Jr, W, Clausing P, Bowyer JF. d-Fenfluramine produces neuronal degeneration in localized regions of the cortex, thalamus, and cerebellum of the rat. Toxicol Sci 1999; 48:100-6.
52. Schulze GE, McMillan DE, Bailey JR, Scallet AC, Ali SF, Slikker Jr, W et al. Acute effects of delta-9-tetrahydrocannabinol (THC) in rhesus monkeys as measured by performance in a battery of cognitive function tests. J Pharmacol Exp Ther 1988;245: 178-86.
53. Slikker Jr, W, Ali SF, Scallet AC, Frith CH, Newport GD, Bailey JR. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988;94:448-57.
54. Slikker Jr, W, Crump KS, Andersen ME, Bellinger D. Biologically based, quantitative risk assessment of neurotoxicants. Fundam Appl Toxicol 1996;29:18-30.
55. Steele TD, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994;89: 539-51.
56. Stewart CW, Bowyer JF, Slikker Jr, W. Elevated environmental temperature can induce hyperthermia during d-fenfluramine exposure and enhance 5-hydroxytryptamine depletion in the brain. J Pharmacol Exp Ther 1997;283:1144-50.
57. Szebenyi ES. Atlas of Macaca mulatta. Rutherford (NJ): University Press; 1970.
58. Walubo A, Seger D. Fatal multi-organ failure after suicidal overdose with MDMA. Hum Exp Toxicol 1999;18:119-25.
59. Young JF, Wosilait WD, Luecke RH. Analysis of methylmercury disposition in humans utilizing a PBPK model and animal pharmacokinetic data. J Toxicol Environ Health Part A 2001; 63:19-52.